Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani

Drug Delivery

Volumn 22, Issue 3, 2015, Pages 383-388

  Kumar, Rishikesh ^a   Sahoo, Ganesh Chandra ^a   Pandey, Krishna ^b   Das, Vnr ^b   Das, Pradeep ^a,b  

^a Rajendra Memorial Research Institute of Medical Science   (India)

^b Rajendra Memorial Research Institute of Medical Science   (India)

Author keywords

Amastigotes; Amphotericin B; Electron microscope; Kala azar; Nanometer; PLGA PEG; Promastigote

Indexed keywords

AMPHOTERICIN B; MACROGOL; NANOPARTICLE; POLYGLACTIN; ANTIPROTOZOAL AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FEMALE; INFRARED SPECTROSCOPY; LEISHMANIA DONOVANI; LIGHT SCATTERING; MACROPHAGE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROMASTIGOTE; TRANSMISSION ELECTRON MICROSCOPY; VISCERAL LEISHMANIASIS; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; DRUG SENSITIVITY; HAMSTER; LEISHMANIASIS, VISCERAL; PARASITOLOGY; SPLEEN; SURFACE PROPERTY;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARASITIC SENSITIVITY TESTS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; SPLEEN; SURFACE PROPERTIES;

EID: 84930456687     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.891271     Document Type: Article

References (14)

1. Bolard J, Legrand P, Heitz F, Cybulska B. (1991). One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-Association in the medium. Biochem 30: 5707-15.
2. Croft SL, Sundar S, Fairlamb AH. (2006). Drug Resistance in Leishmaniasis. Clin Microbiol Rev 19:111-26.
3. Gershkovich P, Wasan EK, Lin M, et al. (2009). Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 64:101-8.
4. Handman E, Bullen DV. (2002). Interaction of Leishmania with the host macrophage. Tren Parasitol 1:332-4.
5. Hartsel S, Bolard J. (1996). Amphotericin B, new life for an old drug. Tren Pharmacol Sci 17:446-9.
6. Iqbal J, Hira PR, Saroj G, et al. (2002). Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol 40:475-9.
7. Kreuter J. (2005). Liposomes and nanoparticles as vehicles for antibiotics. Infection 19:224-8.
8. Mc Conville MJ, Mullin KA, Ilgoutz SC, Teasdale RD. (2002). Regulated degradation of ER membrane proteins in a novel tubular lysosome in Leishmania mexicana. Microbiol Mol Biol Rev 66:122-54.
9. Muller RH, Jacobs C, Kayser O. (2001). Nano-suspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19.
10. Mundargi RC, Babu VR, Rangaswamy V, et al. (2008). Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J Control Release 25: 193-209.
11. Späth GF, Garraway LA, Turco SJ, Beverley SM. (2003). The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A 100: 9536-41.
12. Sundar S, More DK, Singh MK, et al. (2000). Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104-7.
13. World health organization. (1999). Wkly Epidemiol Rec 74: 365-76.
14. Yoshiaki K. (2001). Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 47:1-2.